PUBLIC COMPANY
saveGENENTECH
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Vistagen cuts workforce for second time in 2026Follow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 12h ago
- Anthropic's Nathan Frey on biopharma partners, M&A and pipelineNathan Frey has stayed busy since Anthropic acquired his biotech startup Coefficient Bio this spring. The former Genentech machine-learning scientist now leads drug discovery and development resear…endpoints · 3d ago
- Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitionsRoche's Genentech has put numbers behind its phase 3 success in IgA nephropathy (IgAN), reporting that antisense oligonucleotide sefaxersen reduced a key marker of kidney damage by 43.1% compared w…fiercebiotech · 10d ago
- Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyoutRoche’s CEO has insisted to Fierce that the company’s view on its $1.5 billion Poseida buyout has “absolutely not” changed, even as the Swiss pharma scraps one of the CAR-T therapy’s from the acqui…fiercebiotech · 11d ago
- Lycia aims for $228M IPO to generate data on food allergy rival to XolairLycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for autoimmune, inflammatory and allergic diseases.fiercebiotech · 13d ago
- Ex-Genentech scientist joins Ira Mellman at Medici; Intellia poaches CMO from Scholar Rock→ More former Genentech leaders are finding a new home. Lélia Delamarre posted on LinkedIn that she’s leading R&D at ARCH-backed cancer biotech Medici Therapeutics, one of this year’sendpoints · 17d ago
- Why OMass’ $310M series C marks ‘fantastic milestone’ on journey to become ‘Britain’s Big Biotech’When Fierce last caught up with OMass Therapeutics’ CEO Ros Deegan, it was hard not to be impressed by the company’s ambition.fiercebiotech · 19d ago
- Roche sets sights on FDA approval decision of July 2027 with updated eye drug dataOne year on from a mixed phase 3 readout, Roche has shared updated data from eye disease trials that could support FDA approval by July.fiercebiotech · 21d ago
- Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potentialMerck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led analysts to predict “limited competitive potential” in diabetic macular ede…fiercebiotech · 22d ago
- Robotics company Multiply Labs nets $75M; Isotope maker NorthStar gets up to $185MPlus, news about Roche’s Genentech and Fresenius Kabi. Multiply Labs collects $75M: The robotics biomanufacturing company’s Series B raise will be used to increase its capacity and headcount as it…endpoints · 25d ago
comments(0)
5-min edit window · permanent after that